Health utilities for the adverse- and intermediate-risk Markov decision analyses
| Utility . | Value . | References . |
|---|---|---|
| Adverse- and intermediate-risk model | ||
| DFS if treated with AZ | 0.8 | Patel et al30 |
| Relapse if treated with AZ | 0.67 | Patel et al30 |
| DFS if treated with IC | 0.83 | Tremblay et al31 |
| Relapse if treated with IC | 0.53 | Tremblay et al31 |
| Utility . | Value . | References . |
|---|---|---|
| Adverse- and intermediate-risk model | ||
| DFS if treated with AZ | 0.8 | Patel et al30 |
| Relapse if treated with AZ | 0.67 | Patel et al30 |
| DFS if treated with IC | 0.83 | Tremblay et al31 |
| Relapse if treated with IC | 0.53 | Tremblay et al31 |
AZ, azacitidine and venetoclax